Shr-1918 for high cholesterol not controlled on statins and PCSK9 inhibitors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional, phased study evaluates the efficacy and safety of SHR-1918 in adults with hypercholesterolemia who remain above target LDL-C despite statin and PCSK9 inhibitor therapy. Participants receive SHR-1918 injections or placebo, with outcomes assessed at 12 and 24 weeks. The trial excludes individuals with severe heart failure, recent major ASCVD events, or significant drug allergies, and requires adherence to contraception where applicable. Lead sponsorship is from Beijing Suncadia Pharmaceuticals, with the study conducted at Nanjing First Hospital in China.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Male and female ≥ 18 years old and ≤ 85 years old, who is able and willing to provide a written informed consent.
2. TG ≤ 5.6 mmol/L.
3. LDL-C ≥ 2.6 mmol/L for moderate to high ASCVD risk, LDL-C ≥ 1.8 mmol/L for very high ASCVD risk, LDL-C ≥ 1.4 mmol/L for ultra-high ASCVD risk.
4. Male and female subjects of childbearing potential and their partners must have no plans to donate sperm or become pregnant during the entire study period and after the last dose, and agree to use contraceptive methods as specified in the protocol.

Exclusion Criteria:

1. History of severe allergies/hypersensitivity reactions, or clinically significant allergies/hypersensitivity reactions as judged by the investigator, or history of allergies to drugs with similar chemical structures.
2. Heart failure with New York Heart Association (NYHA) Class III-IV prior to screening or randomization.
3. Acute ischemic ASCVD events within 3 months prior to screening or randomization.
4. Have severe cardiac arrhythmia within 3 months prior to screening or randomization.
5. Echocardiography indicates a left ventricular ejection fraction (LVEF) of less than 30% within 3 months prior to screening.
6. History of percutaneous coronary intervention, history of coronary artery bypass grafting (CABG), history of peripheral arterial revascularisation within 1 month prior to screening or randomization.
7. Poorly controlled type 2 diabetes mellitus or previously diagnosed type 1 diabetes mellitus; poorly controlled hypertension.
8. Have a history of diseases that significantly affect blood lipid levels, such as nephrotic syndrome, severe liver diseases, Cushing's syndrome, or have severe arrhythmia prior to screening or randomization.
9. Malignant tumors within 5 years.
10. It's planned to research transcutaneous coronary intervention, coronary artery bypass grafting, carotid or peripheral artery reconstruction, pacemaker implantation, cardiac resynchronisation therapy (CRT), implantable cardioverter defibrillator (ICD) implantation and other implantations during the study.
11. Received plasma exchange therapy within 2 months prior to screening, or plans to receive plasma exchange therapy during the study period, or has received LDL receptor gene therapy prior to screening.
12. Have a history of major surgery within 3 months prior to screening, or plans to undergo major surgery during the study period.
13. History of drug use, substance abuse, and alcohol abuse.
14. Participated in or is participating in other clinical studies and has received study interventions within the past month prior to screening.
15. Researchers determine that the subject has poor compliance or any factors that make them unsuitable for participation in this trial, including but not limited to participation in the study placing the subject at unacceptable risk or potentially interfering with the study results.

Where it's running

• Nanjing First Hospital
  Nanjing, Jiangsu, China Recruiting

Study contacts

• Study coordinator: Miaomiao Shi
• Email: miaomiao.shi@hengrui.com
• Phone: +86-0518-82342973

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• VERVE-102 for adults with or at high risk for heart disease

  This study tests whether VERVE-102 can lower bad cholesterol (LDL-C) compared with a placebo in adults with plaque buildup or high risk for it.

  Recruiting Phase 2 Verve Therapeutics, Inc. · DeSoto, Texas · NCT07839936

• Enlicitide (MK-0616) for adults with high cholesterol in India

  This study tests whether enlicitide helps lower bad cholesterol (LDL-C) compared with placebo in adults with hyperlipidemia/hypercholesterolemia.

  Recruiting at 2 sites Phase 3 Merck Sharp & Dohme LLC · Belagavi, Karnataka and 1 other locations · NCT07821944

• Pemafibrate in people with high cholesterol not fully controlled by statins

  This study tests whether taking Pemafibrate at 0.2 mg or 0.4 mg daily for 12 weeks helps people with high cholesterol who still don’t respond well to statins, compared with a placebo.

  Recruiting at 10 sites Phase 4 Kowa Company, Ltd. · Hokkaido and 9 other locations · NCT07634484

• Dual PCSK9 Inhibition in secondary prevention for high LDL-C with statin intolerance

  This study tests whether combining inclisiran and alirocumab lowers LDL cholesterol better than either drug alone in people with ASCVD who can’t tolerate statins.

  Recruiting Phase 4 University Medical Centre Ljubljana · Ljubljana · NCT07581808

• Moderate-Intensity Statin + Ezetimibe vs High-Intensity Statin in CKD with ASCVD

  In adults with chronic kidney disease and established cardiovascular disease, this study tests whether a moderate-intensity statin plus ezetimibe can match the benefits of a high-intensity statin alone over three years.

  Recruiting Yonsei University · Seoul · NCT07524101

• Corn oil versus avocado oil effects on cardiometabolic risk factors

  This trial will test whether following controlled diets containing either corn oil or avocado oil for 21 days changes cardiometabolic risk factors in adults with mildly to moderately high non‑HDL cholesterol.

  Recruiting Midwest Center for Metabolic and Cardiovascular Research · Addison, Illinois · NCT07514663

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.